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Abstract
Objective—Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus 
nephritis in previous studies. We studied anti-C1q specificity for SLE (vs. rheumatic disease 
controls) and the association with SLE manifestations in an international multi-center study.
Methods—Information and blood samples were obtained in a cross-sectional study from patients 
with SLE (n=308) and other rheumatologic diseases (n=389) from 25 clinical sites (84% female, 
68% Caucasian, 17% African descent, 8% Asian, 7% other). IgG anti-C1q against the collagen-
like region was measured by ELISA.
Results—Prevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in 
controls (OR=2.7, 95% CI: 1.8-4, p<0.001). Anti-C1q was associated with proteinuria (OR=3.0, 
95% CI: 1.7-5.1, p<0.001), red cell casts (OR=2.6, 95% CI: 1.2-5.4, p=0.015), anti-dsDNA 
(OR=3.4, 95% CI: 1.9-6.1, p<0.001) and anti-Smith (OR=2.8, 95% CI: 1.5-5.0, p=0.01). Anti-C1q 
was independently associated with renal involvement after adjustment for demographics, ANA, 
anti-dsDNA and low complement (OR=2.3, 95% CI: 1.3-4.2, p<0.01). Simultaneously positive 
anti-C1q, anti-dsDNA and low complement was strongly associated with renal involvement 
(OR=14.9, 95% CI: 5.8-38.4, p<0.01).
Conclusions—Anti-C1q was more common in patients with SLE and those of Asian race/
ethnicity. We confirmed a significant association of anti-C1q with renal involvement, independent 
of demographics and other serologies. Anti-C1q in combination with anti-dsDNA and low 
complement was the strongest serological association with renal involvement. These data support 
the usefulness of anti-C1q in SLE, especially in lupus nephritis.
Introduction
Complement plays a major role in the pathogenesis of systemic lupus erythematosus (SLE) 
and lupus nephritis. Genetic deficiencies in the early complement components are associated 
with SLE 1, 2. The strongest association is seen in patients with homozygous C1q deficiency, 
of whom 88% developed SLE and 30% glomerulonephritis, respectively 3. In vitro, 
physiologic concentrations of C1q inhibit interferon alpha production by plasmacytoid 
dendritic cells stimulated with nucleic acid containing immune complexes 4, suggesting a 
regulatory effect of C1q in response to and clearance of immune complexes. In patients with 
SLE, levels of C1q were reduced in glomerulonephritis flares 5. In patients with lupus 
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nephritis, the presence of anti-C1q at the time of renal biopsy was associated with worse 
renal outcome, by the American College of Rheumatology (ACR) renal response criteria 6, 
and with renal tubulointerstitial changes 7. Acquired antibodies against the collagen-like 
region of C1q (anti-C1qCLR) were present in the glomerular basement membrane of 
patients with proliferative lupus nephritis at concentrations more than 50 fold higher per unit 
IgG than in the patients’ serum, suggesting a role in the pathogenesis of lupus nephritis 8. 
C1q were aggregated within immunoglobulin G in renal subendothelial deposits in active 
proliferative lupus nephritis as seen on immunogold electron microscopy, further supporting 
a pathogenic role of anti-C1q 9. Patients with active lupus nephritis had a higher prevalence 
of anti-C1q than those without lupus nephritis, 74% versus 32% (p<0.0001) 10. Anti-C1q 
increased within 6 months prior to renal involvement in 50% of patients with SLE 11 and 
were associated with the proliferative form of glomerulonephritis 1214. In another study, an 
increase in anti-C1q level preceded renal flare by 2.3 months and was more specific for 
renal flare than increases in anti-dsDNA level 15. Anti-C1q concentration correlated with 
activity on the modified SELENA-SLEDAI and the SLICC Renal Activity Score 16. With 
immunosuppressive treatment for membranoproliferative lupus nephritis with either 
cyclophosphamide or azathioprine, anti-C1q disappeared by week 12 and remained 
undetectable throughout one year of follow-up 17. As detailed above, evidence suggests that 
anti-C1q is associated, not only with lupus nephritis, but also with lupus nephritis flares and 
response to treatment. Therefore anti-C1q might be a candidate for predicting lupus nephritis 
and monitoring treatment in clinical practice. The purpose of this study was to characterize, 
in a multinational patient population, the prevalence and clinical associations of anti-C1q in 
patients with SLE and other rheumatic diseases and to define the association of anti-C1q 
with renal involvement in patients with SLE.
Patients and methods
Patients
We studied anti-C1q specificity for SLE (vs. rheumatic disease controls) and its association 
with SLE manifestations in an international, multi-center, cross-sectional sample of patients 
with SLE and other rheumatic diseases, assembled to derive the Systemic Lupus 
Collaborating Clinics (SLICC) classification criteria for SLE 18.
Laboratory methods
Anti-C1q determination was performed at the laboratory of Lennart Truedsson MD, PhD 
(Department of Microbiology and Clinical Immunology, Lund University Hospital, 
Sweden). An enzyme-linked immunosorbent assay (ELISA) with purified collagenous C1q 
fragments in the solid phase was used for detection of anti-C1q IgG in all serum samples 
obtained in the beginning of the study. The assay was previously described 19 and it is well 
documented that autoantibodies against C1q in SLE target the collagenous portion of the 
molecule 20, 21. Use of purified C1q collagenous fragments as antigen in the ELISA 
prevented non-specific interactions. The reference interval was defined as < 16 AU/L based 
on analysis of anti-C1q IgG in 96 healthy blood donors 22.
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Laboratory determinations were performed at the Rheumatology Diagnostic Laboratory (Los 
Angeles, CA) for anti-dsDNA by enzyme-linked immunosorbent assay (ELISA), Crithidia 
assay and Farr assay, and for anti-Smith antibody and complement C3 and C4 levels. 
Another set of blood samples were tested for antiphospholipid antibodies (lupus 
anticoagulant, and ELISA for IgG, IgM, and IgA isotypes of anticardiolipin antibodies and 
anti-β2-glycoprotein I antibodies) at the laboratory of Joan Merrill, MD (Oklahoma Medical 
Research Foundation).
Statistical methods
Statistical analyses were carried out using SAS® (SAS® 9.2, SAS Institute Inc., Cary, North 
Carolina, USA) and Stata statistical software (Stata 12, StataCorp LP, College Station, 
Texas, USA). Patients with SLE and controls with rheumatic disease were compared with 
respect to demographic characteristics, clinical manifestations, and serologic results using 
Chi-square tests; p-values for Chi-square tests were adjusted for age and ethnicity as 
specified in the tables. A p-value ≤ 0.05 was considered statistically significant. In patients 
with SLE, we calculated odds ratios of renal involvement, by the SLICC classification 
criteria (urine protein to creatinine ratio or 24-hour urine protein representing 500mg/24 
hours or red blood cell casts) 23, using multiple logistic regression on demographic and 
serologic characteristics. The first model adjusted for demographics (age, ethnicity, gender) 
and individual antibodies (ANA, anti-dsDNA, low complement C3 and/or C4 and anti-C1q). 
The second model adjusted for demographics and serologic patterns for anti-C1q, anti-
dsDNA and low complement C3 and/or C4.
The study was approved by institutional review boards at all institutions involved, and all 
participants provided written informed consent.
Results
Clinical information and blood samples were obtained from 308 patients with SLE ( mean 
age (SD) 34 (13) years, 89% female, 63% Caucasian, 22% African descent, 12% Asian, 3% 
other) and 389 patients with other rheumatologic diseases (mean age (SD) 43 (15) years, 
80% female, 73% Caucasian, 13% African descent, 5% Asian, 9% other) from 25 clinical 
sites. SLICC renal involvement was present in 33% of patients with SLE and 4% of 
controls. Of 308 patients with SLE, 72 (23%) had biopsy confirmed lupus nephritis (and 
none of the controls).
Anti-C1q prevalence by diagnosis
The prevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in 
controls with other rheumatologic disorders (OR=2.7, 95% CI 1.8-4.0, p <0.001). The 
frequency of anti-C1q in rheumatic disease controls was: 26% in scleroderma, 19% in 
rheumatoid arthritis, 15% in undifferentiated connective tissue disease, 15% in chronic 
cutaneous lupus, 14% in Sjögren syndrome, 8% in fibromyalgia, 7% in antiphospholipid 
antibody syndrome, 6% in dermatomyositis, and 5% in vasculitis.
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Anti-C1q and demographic characteristics in patients with SLE
Anti-C1q was more common in Asians (n=37, 40.5%) than in Caucasians (n=192, 27.6%) or 
patients of African descent (n=69, 21.7%), but these differences were not statistically 
significant. Anti-C1q was more common in younger individuals with SLE, using an age cut-
off of 30 years (35.5% versus 23%, p=0.02) (Table 1).
Anti-C1q and clinical SLE manifestations
Sensitivity of anti-C1q for a classification of SLE was 28% and specificity was 87%. In an 
age adjusted analysis we assessed the clinical features of SLE associated with anti-C1q 
antibodies. Patients with anti-C1q were significantly more likely to have proteinuria 
(OR=3.0, 95% CI 1.7 - 5.1, p<0.001) and urinary red cell casts (OR=2.6, 95% CI 1.2 - 5.4, 
p=0.015). There was a trend towards an association with psychosis (OR=9.5, 95% CI 0.9 – 
98.5, p=0.06). No significant associations were seen with arthritis, cutaneous lupus or 
hematologic manifestations (Table 2).
Anti-C1q and serologic SLE manifestations
In patients with SLE positive for anti-C1q (compared to patients negative for anti-C1q), 
there were positive associations with anti-dsDNA (OR=3.4, 95% CI 1.9 – 6.1, p<0.001) and 
anti-Smith (OR=2.8, 95% CI 1.5 – 5.0, p=0.01) and no association with antiphospholipid 
antibodies after adjustment for age (Table 2).
Anti-C1q and lupus nephritis
Sensitivity of anti-C1q for SLE renal involvement was 41% and specificity was 85%. Anti-
C1q prevalence in patients with SLE with, versus without ACR renal disorder (persistent 
proteinuria > 0.5 g/24h or proteinuria > 3+, or red blood cell casts) was 45.5% compared to 
19.3%, respectively (OR=3.2, 95% CI 1.8 – 5.6, p<0.001). Additional serologic associations 
observed for ACR renal disorder were with anti-dsDNA (OR=4.7, 95% CI 2.5 – 8.6, 
p<0.001), low complement (OR=2.8, 95% CI 1.5 – 4.9, p=0.001) and anti-Smith (OR=1.9, 
95% CI 1.1 – 3.6, p=0.03), after adjustment for age and ethnicity (Table 3).
The first logistic regression model was applied to all patients with SLE (n=308) to estimate 
the independent contribution of demographic characteristics and serologies to odds of 
SLICC renal involvement (n=101). Odds of SLICC renal involvement were two times lower 
in patients above age 30 than below age 30 (OR=0.4, 95% CI 0.3 – 0.8, p=0.005) and, 
independently of age, three times lower in Caucasians compared to African-Americans 
(OR=0.3, 95% CI 0.1 – 0.6, p<0.001), after adjustment for gender and serologies (Table 4).
Odds of SLICC renal involvement in the presence of anti-dsDNA were 4 times higher than 
in the absence of anti-dsDNA, after adjustment for age, ethnicity, gender and serologies (OR 
=4.1, 95% CI 2.1 – 7.9, p<0.001). In the same model, for anti-C1q positive, odds of SLICC 
renal involvement were independently 2.3 times higher than in the absence of anti-C1q 
(OR=2.3, 95% CI 1.3 – 4.2, p=0.007) (Table 4). Low complement C3 and/or C4, compared 
to normal, was associated with double the odds of SLICC renal involvement, a finding that 
was not statistically significant after adjustment for anti-dsDNA and anti-C1q (OR =1.9, 
95% CI 1.0 – 3.6, p=0.06).
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The second logistic regression model estimated odds of SLICC renal involvement using 
possible combinations of serology results for anti-dsDNA, anti-C1q and low complement 
and adjusted for age, ethnicity and gender. By patterns of positivity for anti-C1q, anti-
dsDNA and low complement, odds of SLICC renal involvement were 15 times higher for 
patients with all three serologies positive compared to all negative (OR=14.9, 95% CI 5.8 – 
38.4, p<0.001). In the same model, combinations of simultaneously positive anti-dsDNA 
and low complement, and simultaneously positive anti-dsDNA and anti-C1q were associated 
with 5 times and 6 times increase in odds of SLICC renal involvement than all three 
serologies negative, respectively (OR=5.2 95% CI 2.1 – 13.1, p<0.001 and OR=5.7 95% CI 
1.2 – 28.3, p=0.03) (Table 5).
Discussion
Anti-C1q has been associated with SLE and SLE nephritis in previous studies 10, 12, 14, 24-28. 
We confirmed this association in the SLICC international patient population, in which we 
studied 308 patients with SLE and 389 controls with other rheumatologic diseases. We also 
showed, for the first time, the association of anti-C1q with lupus renal involvement by 
SLICC classification criteria.
The presence of anti-C1q antibodies in other autoimmune diseases, as we have found, and 
even in healthy individuals (4% to 6.4%), has been previously reported 2129. Patients with 
scleroderma were anti-C1q positive in a higher proportion in our study, 26%, than observed 
in other studies, 5.5% 24. None of these patients had renal involvement. Patients with 
rheumatoid arthritis were anti-C1q positive in a higher proportion in our study, 19%, than 
observed in other studies, 5% 30. However, a review by Seelen MA et al. reported anti-C1q 
prevalence of 77% in rheumatoid vasculitis 31. Patients with vasculitis were less often 
positive in the population we studied, 5%, versus 12 35% in other studies 29. We did not 
collect information on type of vasculitis and ANCA status. Anti-C1q has not been 
previously described in dermatomyositis in which we found a prevalence of anti-C1q of 6% 
(based on 55 patients). Anti-C1q were more common in Asians (40.5%) than in Caucasians 
(27.6%) and patients of African descent (21.7%), but these differences were not statistically 
significant, consistent with previous studies 32. We found that younger individuals with SLE 
were more likely to be anti-C1q positive than older individuals, using an age cutoff of 30 
years. Siegert et al., similarly, found a higher prevalence of IgG anti-C1q antibodies in 
younger individuals with SLE compared to random selected controls (highest titer and 
highest prevalence below age 30); in patients with SLE anti-C1q prevalence decreased with 
age while in random controls the opposite was true 33. Anti-C1q antibody prevalence in 
patients with SLE with ACR renal involvement was 45.5% in our study. Braun et al. found a 
prevalence of 61.7% in biopsy proven lupus nephritis cases 29 and Wener et al., 48% 21. The 
strongest clinical association we observed for anti-C1q was with proteinuria, consistent with 
published data 12, 14, 16, 27, 34. Our study was undertaken in patients with SLE from a 
multicenter, multiethnic patient population and an equal number of patients with other 
rheumatic diseases (controls), in which complete clinical, serologic and candidate criteria 
variables were assessed for the purpose of deriving SLE classification rules. We did not 
have flare data, treatment data, or repeat anti-C1q antibody levels, because of the cross-
sectional nature of this study. Therefore, any temporal relationship of anti-C1q antibody 
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levels to flares of lupus nephritis or change in treatment could not be assessed. Others noted 
that anti-C1q antibody levels increased prior to flares of lupus nephritis and disappeared 
with immunosuppressive treatment 111526. Moroni G. et al. showed an association with 
active lupus nephritis for anti-C1q and low complement 14. Yang XW et al. showed 
concomitant presence of anti-C1q and anti-dsDNA was associated with higher lupus 
nephritis activity and poor renal outcome compared to only one or none of these 
antibodies 28. Anti-C1q in our study had the highest prevalence in patients with SLE with 
ACR renal involvement and was strongly associated with anti-dsDNA and low complement. 
It was the second highest antibody associated with a diagnosis of ACR renal involvement, 
after anti-dsDNA. By the SLICC classification criteria, age above 30 years and being 
Caucasian were protective from SLICC renal involvement: these characteristics were 
independently associated with decreased odds of renal involvement in patients with SLE by 
two and three times, respectively, which is consistent with the literature on the subject. 
Independently of each other, anti-dsDNA (versus negative) was associated with 4 times 
higher odds of SLICC renal involvement and anti-C1q (versus negative) was associated with 
two times higher odds of SLICC renal involvement, after adjustment for age, ethnicity, 
gender and low complement. In patients with SLE, odds of SLICC renal involvement were 
highest in the presence of simultaneously positive anti-dsDNA, anti-C1q and low 
complement (15 times higher than all negative). Increases in odds of SLICC renal 
involvement with concomitantly positive anti-dsDNA and low complement were similar to 
concomitantly positive anti-dsDNA and anti-C1q. As seen in the logistic regression models, 
the three serologies (anti-C1q, anti-dsDNA, low complement) had a multiplicative 
relationship in increasing the odds of SLICC renal involvement, after adjustment for 
demographics.
Many studies of anti-C1q antibodies are performed with methods using whole C1q 
molecules as antigen and a buffer with high ionic strength to prevent nonspecific interaction 
between the globular heads of C1q and antibodies. In this study the purified collagenous 
fragment was used as antigen in the ELISA and the nonspecific interactions were thereby 
avoided 19. Comparisons between the method used here and the high salt buffer method in 
100 patients with high and low disease activity have given very similar results (Truedsson et 
al., pers communication). The reason anti-C1q was eliminated, at the end of the derivation 
phase of the SLICC classification criteria for SLE, was mainly because of a lack of a high 
quality, standardized, less laborious assay. As new laboratory techniques develop and 
further uses of anti-C1q determinations become important for clinical care and disease 
prognosis, anti-C1q can be reconsidered for inclusion in classification criteria and in the 
clinical management of SLE.
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Table 1
Association between Demographic Characteristics and Anti-C1q in SLE: Percentage of Patients with Anti-
C1q, by Demographic Variables
Demographics Percentage for Anti-C1q p-value
Ethnicity
    African Descent 21.7 0.15
    Caucasian 27.6
    Asian 40.5
    Other 30.0
Gender
    Female 26.9 0.25
    Male 36.4
Age (years)
    ≤30 35.5 0.01
    >30 23.0
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Table 2
Association between ACR Criteria and Anti-Clq in SLE: Percentage of Patients with Various Clinical 
Conditions, by Anti-C1q Status
ACR Criteria Anti-C1q Positive (%) Anti-C1q Negative (%) p-value Odds Ratio (95% CI) Adjusted p-value for Age
Malar Rash 47.7 46.9 0.90 0.9 (0.5, 1.5) 0.69
Discoid Rash 19.8 19.4 0.94 1.1 (0.6, 2.1) 0.71
Photosensitivity 53.5 53.2 0.96 1.0 (0.6, 1.7) 1.00
Oral Ulcers 38.4 46.4 0.20 0.7 (0.4, 1.1) 0.14
Arthritis 64.0 65.8 0.76 0.9 (0.5, 1.5) 0.70
Serositis 37.2 34.7 0.68 1.1 (0.6, 1.8) 0.84
Pleurisy 31.4 28.4 0.60 1.1 (0.6, 1.9) 0.74
Pericarditis 14.0 12.2 0.67 1.2 (0.6, 2.5) 0.66
Proteinuria 50.0 22.5 <0.01 3.0 (1.7, 5.1) <0.01
Red cell casts 18.6 7.2 <0.01 2.6 (1.2, 5.4) 0.02
Seizure 5.8 4.1 0.51 1.2 (0.4, 3.8) 0.72
Psychosis 3.5 0.5 0.04 9.5 (0.9, 98.5) 0.06
Hematologic 64.0 58.1 0.35 1.2 (0.7, 2.0) 0.49
Leukopenia 40.7 35.1 0.36 1.2 (0.7, 2.0) 0.48
Lymphopenia 38.4 36.5 0.76 1.1 (0.7, 1.8) 0.73
Thrombocytopenia 15.1 12.2 0.49 1.1 (0.5, 2.2) 0.86
Anti-dsDNA 77.9 47.8 <0.01 3.4 (1.9, 6.1) <0.01
Anti-Smith 33.7 14.4 <0.01 2.8 (1.5, 5.0) 0.01
Antiphospholipid 57.0 54.5 0.70 1.1 (0.7, 1.8) 0.70
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Table 3
Association with Renal involvement: Percentage of Patients with SLE Serologies among those with and 
without ACR Lupus Nephritis
Variable Renal involvement (%) No Renal involvement 
(%)
p-value Odds Ratio (95% CI) Adjusted p-value for Age 
and Ethnicity
Anti-C1q 45.5 19.3 <0.01 3.2 (1.8, 5.6) <0.01
Anti-dsDNA 80.2 44.4 <0.01 4.7 (2.5, 8.6) <0.01
Anti-Smith 29.7 15.0 <0.01 1.9 (1.1, 3.6) 0.03
Low complement 78.2 50.2 <0.01 2.8 (1.5, 4.9) <0.01






















ORBAI et al. Page 14
Table 4
Odds ratios (OR) of SLICC renal involvement 
a
 in patients with SLE (N=308) by individual antibody status, 
adjusted for demographic and serologic characteristics
Covariates SLICC renal (OR) 95% CI p-value
Age (years)
    ≤30 (ref.)
b 1.00
    >30 0.44 0.25 – 0.78 <0.01
Ethnicity
    African American (ref.) 1.00
    White 0.28 0.14 – 0.60 <0.01
    Asian 0.42 0.16 – 1.08 0.07
    Hispanic/Latino 0.40 0.09 – 1.71 0.22
Gender
    Male (ref.) 1.00
    Female 0.46 0.19 – 1.14 0.09
ANA 0.22 0.05 – 1.01 0.05
Anti-dsDNA 4.05 2.10 – 7.90 <0.01
Low Complement 1.87 0.98 – 3.59 0.06
Anti-Clq 2.30 1.26 – 4.19 <0.01
a
SLICC renal involvement is defined as urine protein-to-creatinine ratio (or 24-hour urine protein) representing 500mg/24 hours or red blood cell 
casts; estimates from multivariable logistic regression model, constant term 3.44, 95% CI 0.51 – 23.07, p-value 0.2)
b
ref. denotes the reference group for each category
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Table 5
Odds ratios (OR) of SLICC renal involvement 
a
 in patients with SLE (N=308) by antibody patterns, adjusted 
for demographics (age, ethnicity and gender)
Serologic patterns N (308) SLICC renal (OR*) 95% CI p-value
Anti-C1q Anti-dsDNA Low Complement
Negative (ref.) 
b Negative Negative 75 1.00
Negative Negative Positive 41 1.83 0.62 – 5.34 0.27
Negative Positive Negative 35 2.46 0.79 – 7.61 0.12
Negative Positive Positive 71 5.23 2.10 – 13.05 <0.01
Positive Negative Negative 6 4.06 0.60 – 27.30 0.15
Positive Negative Positive 13 0.66 0.07 – 6.11 0.72
Positive Positive Negative 9 5.74 1.16 – 28.29 0.03
Positive Positive Positive 58 14.89 5.77 – 38.44 <0.01
a
SLICC renal involvement is defined as urine protein-to-creatinine ratio (or 24-hour urine protein) representing 500mg/24 hours or red blood cell 
casts; estimates of odds ratios (OR) are from multivariable logistic regression model, constant term 0.95, 95% CI 0.26 - 3.49, p-value 0.94)
b
ref. denotes the reference group for each category
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